Latest Marshall Edwards Inc. Stories
Pre-clinical studies presented at the 9th International Conference on Membrane Redox Systems in Wellington New Zealand this week demonstrate that Novogen's NV-128 (a novel mTOR inhibitor), when used in combination with the Marshall Edwards, Inc.'s Phase III anti-ovarian cancer drug, phenoxodiol, produces potent synergistic anti-cancer activity against non-small cell lung carcinoma cell lines (NSCLC).
Marshall Edwards, Inc. (NASDAQ: MSHL) will present at the Canaccord Adams 28th Annual Global Growth Conference on Wednesday 13 August, 2008. About Marshall Edwards, Inc.: Marshall Edwards, Inc. is a specialist oncology company focused on the clinical development of novel anti-cancer therapeutics.
Marshall Edwards, Inc. (NASDAQ: MSHL) announced today that it entered into a Securities Subscription Agreement with Novogen Limited and OppenheimerFunds, Inc.
Marshall Edwards, Inc.
- An armed gangster.